Aurora Cannabis Advances Powdery Mildew-Resistant Cultivar Research, Commercialization Imminent
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: PRnewswire
- Research Breakthrough: Aurora Cannabis has made significant progress in developing powdery mildew-resistant cultivars, successfully transferring PM2 resistance into elite breeding lines through multiple rounds of crosses, which is expected to enhance product quality and reduce operational costs.
- Production Trial Phase: The company has initiated production trials for PM2-resistant cultivars at its Aurora Ridge facility, validating scientific findings and laying the groundwork for future commercialization, marking a critical step in establishing leadership in cannabis cultivation.
- Industry Influence: Aurora has shared its research findings at various international conferences, showcasing its innovative capabilities in cannabis science and further solidifying its competitive advantage in the global market.
- Intellectual Property Protection: The proprietary genetic marker technology behind PM2 is currently patent pending in Canada, the United States, Europe, and other regions, and successful production trials could generate new revenue streams and elevate industry standards.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 4.320
Low
4.32
Averages
4.32
High
4.32
Current: 4.320
Low
4.32
Averages
4.32
High
4.32
No data
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
